AU2001252458A1 - Molecular antigen arrays and vaccines - Google Patents
Molecular antigen arrays and vaccinesInfo
- Publication number
- AU2001252458A1 AU2001252458A1 AU2001252458A AU5245801A AU2001252458A1 AU 2001252458 A1 AU2001252458 A1 AU 2001252458A1 AU 2001252458 A AU2001252458 A AU 2001252458A AU 5245801 A AU5245801 A AU 5245801A AU 2001252458 A1 AU2001252458 A1 AU 2001252458A1
- Authority
- AU
- Australia
- Prior art keywords
- vaccines
- antigen arrays
- molecular antigen
- molecular
- arrays
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000003491 array Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20234100P | 2000-05-05 | 2000-05-05 | |
US60/202,341 | 2000-05-05 | ||
PCT/IB2001/000741 WO2001085208A2 (en) | 2000-05-05 | 2001-05-02 | Molecular antigen arrays and vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001252458A1 true AU2001252458A1 (en) | 2001-11-20 |
Family
ID=22749482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001252458A Abandoned AU2001252458A1 (en) | 2000-05-05 | 2001-05-02 | Molecular antigen arrays and vaccines |
Country Status (5)
Country | Link |
---|---|
US (2) | US6964769B2 (en) |
EP (1) | EP1278542A2 (en) |
AU (1) | AU2001252458A1 (en) |
CA (1) | CA2407897A1 (en) |
WO (1) | WO2001085208A2 (en) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000032227A2 (en) * | 1998-11-30 | 2000-06-08 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens, method of preparation and use |
US20030138769A1 (en) * | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
WO2002072853A1 (en) * | 2001-03-12 | 2002-09-19 | Ark Therapeutics Limited | Avidin-pseudotyped viral vectors and their use |
US20040146524A1 (en) * | 2002-02-21 | 2004-07-29 | Katelynne Lyons | Stabilized immunogenic HBc chimer particles |
DK1450856T3 (en) | 2001-09-14 | 2010-05-31 | Cytos Biotechnology Ag | Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use |
EP1432443B1 (en) * | 2001-10-05 | 2009-01-21 | Cytos Biotechnology AG | Angiotensin peptide-carrier conjugates and uses thereof |
MXPA04002644A (en) | 2001-10-05 | 2004-07-08 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof. |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
EP1441764B1 (en) * | 2001-11-07 | 2008-10-29 | Cytos Biotechnology AG | Antigen arrays comprising rankl for treatment of bone disease |
WO2003059386A2 (en) * | 2002-01-18 | 2003-07-24 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
US7351413B2 (en) | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
ATE521367T1 (en) * | 2002-06-07 | 2011-09-15 | Kentucky Bioproc Llc | FLEXIBLE VACCINE DESIGN AND DELIVERY PLATFORM |
ATE489969T1 (en) * | 2002-06-20 | 2010-12-15 | Cytos Biotechnology Ag | PACKAGED VIRUS-LIKE PARTICLES IN COMBINATION WITH CPG FOR USE AS ADJUVANTS WITH ALLERGENS. MANUFACTURING PROCESS AND USE |
EP1532167B1 (en) | 2002-07-17 | 2012-01-25 | Cytos Biotechnology AG | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
JP5084103B2 (en) * | 2002-07-18 | 2012-11-28 | サイトス バイオテクノロジー アーゲー | Hapten carrier conjugates and uses thereof |
PL375522A1 (en) * | 2002-07-19 | 2005-11-28 | Cytos Biotechnology Ag | Ghrelin-carrier conjugates |
WO2004016282A1 (en) | 2002-07-19 | 2004-02-26 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays |
MXPA05009580A (en) * | 2003-03-07 | 2005-10-19 | Merck & Co Inc | Influenza virus vaccine. |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
CN100560719C (en) | 2003-03-26 | 2009-11-18 | 赛托斯生物技术公司 | The MELAN-A peptide analogue-virus-like-particle conjugates |
ES2217967B1 (en) * | 2003-03-31 | 2006-01-01 | Consejo Sup. Investig. Cientificas | PROCEDURE FOR THE PRODUCTION OF EMPTY VIRAL PARTICLES (VLPS) OF THE INFECTIOUS BURSITIS INDUCTOR VIRUS (IBDV), COMPOSITIONS NEEDED FOR ITS POSITIONING AND ITS USE IN THE DEVELOPMENT OF VACCINES AGAINST IBDV. |
TWI224273B (en) * | 2003-04-10 | 2004-11-21 | Inventec Corp | Switching system for operation priority of I/O unit and method thereof |
BRPI0507002A (en) * | 2004-01-20 | 2007-06-05 | Cytos Biotechnology Ag | vehicles ghrelin conjugates |
ES2307346B1 (en) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | EMPTY CAPSIDES (VLPS (-VP4)) OF THE VIRUS CAUSING THE INFECTIOUS BURSITIS DISEASE (IBDV), ITS PROCESSING PROCEDURE AND APPLICATIONS. |
ES2307345B1 (en) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | CHEMICAL EMPTY CAPSIDES OF THE VIRUS CAUSING THE INFECTIOUS BURSITIS DISEASE (IBDV), ITS PROCEDURE FOR OBTAINING AND APPLICATIONS. |
AR044603A1 (en) | 2004-06-03 | 2005-09-21 | Consejo Nac Invest Cient Tec | ISOLATED CHEMICAL PROTEINS OF LUMAZINE SYNTHEASE MODIFIED FOR THE MULTIPLE PRESENTATION OF MOLECULES AND ITS APPLICATIONS |
AU2005291231B2 (en) * | 2004-10-05 | 2010-12-23 | Cytos Biotechnology Ag | VLP-antigen conjugates and their uses as vaccines |
AU2005298689A1 (en) | 2004-10-25 | 2006-05-04 | Cytos Biotechnology Ag | Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof |
GB0424563D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
MX2007006832A (en) * | 2004-12-13 | 2007-08-07 | Cytos Biotechnology Ag | Il-15 antigen arrays and uses thereof. |
EP1868642B1 (en) * | 2005-03-18 | 2013-05-08 | Cytos Biotechnology AG | Cat allergen fusion proteins and uses thereof |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
ES2310062B1 (en) * | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | PSEUDOVIRAL PARTICLES CHEMICAL EMPTY DERIVED FROM VIRUS CAUSING INFECTIOUS BURSITIS DISEASE (IBDV), PROCEDURE OF OBTAINING AND APPLICATIONS. |
EP2431468A1 (en) | 2005-09-28 | 2012-03-21 | Cytos Biotechnology AG | Interleukin-1 conjugates and uses thereof |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
NZ573622A (en) | 2006-06-12 | 2011-12-22 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
US20080015145A1 (en) * | 2006-07-11 | 2008-01-17 | Maria Gyongyossy-Issa | Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions |
WO2008100609A1 (en) * | 2007-02-16 | 2008-08-21 | The Salk Institute For Biological Studies | A novel antitoxin and vaccine platform based on nodavirus vlps |
JP5209800B2 (en) | 2008-12-09 | 2013-06-12 | ファイザー バクシーンズ エルエルシー | IgECH3 peptide vaccine |
MX2012001194A (en) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof. |
CN102573903B (en) * | 2009-08-07 | 2015-12-02 | 特兰斯吉恩股份有限公司 | Be used for the treatment of the compositions of HBV infection |
EP2470554B1 (en) * | 2009-08-26 | 2017-06-28 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
EP2865752A1 (en) | 2009-09-03 | 2015-04-29 | Pfizer Vaccines LLC | PCSK9 vaccine |
EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
EA037377B1 (en) | 2011-02-11 | 2021-03-22 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Vaccine for inducing an immune response against hbv |
US9238679B2 (en) | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
CN107970440A (en) | 2011-04-29 | 2018-05-01 | 西莱克塔生物科技公司 | Tolerogenesis synthesizes nano-carrier |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
JP2014521687A (en) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
WO2014145205A2 (en) | 2013-03-15 | 2014-09-18 | St. Jude Children's Research Hospital | Methods and compositions of p27kip1 transcription modulators |
MX2015015221A (en) | 2013-05-03 | 2016-07-06 | Selecta Biosciences Inc | Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects. |
EP3003306B1 (en) | 2013-06-04 | 2020-08-26 | Selecta Biosciences, Inc. | Repeated administration of non-immunosupressive antigen specific immunotherapeutics |
WO2015017280A1 (en) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
CA2924733C (en) | 2013-09-29 | 2018-02-27 | St. Jude Children's Research Hospital, Inc. | Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
JP6780852B2 (en) * | 2014-06-02 | 2020-11-04 | アイエスエー ファーマシューティカルズ ビー.ヴイ.ISA Pharmaceuticals B.V. | Synthetic long-chain peptide (SLP) for therapeutic vaccination against hepatitis B virus infection |
WO2015200728A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
CN114146167A (en) | 2014-09-07 | 2022-03-08 | 西莱克塔生物科技公司 | Methods and compositions for attenuating gene expression modulating antiviral transfer vector immune responses |
MA40824A (en) | 2014-10-22 | 2017-08-29 | Saiba Gmbh | MODIFIED VIRUS TYPE CMV PARTICLES |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CN112933094A (en) | 2015-06-18 | 2021-06-11 | 听治疗有限责任公司 | Methods and compositions for preventing and treating hearing loss |
WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
WO2017179025A1 (en) | 2016-04-15 | 2017-10-19 | Alk-Abelló A/S | Epitope polypeptides of ragweed pollen allergens |
CA3021645A1 (en) | 2016-04-29 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
CN109922819A (en) | 2016-09-27 | 2019-06-21 | 西莱克塔生物科技公司 | Recombinant immunotoxin for treating cancer |
MX2019008143A (en) | 2017-01-07 | 2020-01-13 | Selecta Biosciences Inc | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers. |
CA3055936A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
BR112020007157A2 (en) | 2017-10-13 | 2020-09-24 | Selecta Biosciences, Inc. | methods and compositions for the attenuation of viral transfer anti-vector igm responses |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
AU2019308567A1 (en) | 2018-07-16 | 2021-01-28 | Selecta Biosciences, Inc. | Methods and compositions of OTC constructs and vectors |
US20200038463A1 (en) | 2018-07-16 | 2020-02-06 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
CN114126666A (en) | 2019-04-28 | 2022-03-01 | 西莱克塔生物科技公司 | Methods for treating subjects with pre-existing immunity to viral transfer vectors |
AU2020284555A1 (en) | 2019-05-28 | 2021-12-23 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
MX2022004825A (en) | 2019-10-23 | 2022-10-10 | Regeneron Pharma | Synthetic rig-i-like receptor agonists. |
EP4274571A1 (en) | 2021-01-05 | 2023-11-15 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
CA3212571A1 (en) | 2021-03-19 | 2022-09-22 | Trained Therapeutix Discovery, Inc. | Compounds for regulating trained immunity, and their methods of use |
AU2022253064A1 (en) | 2021-04-09 | 2023-10-19 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023064350A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
WO2023086615A1 (en) | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
WO2023183568A1 (en) | 2022-03-25 | 2023-09-28 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204096A (en) * | 1984-03-07 | 1993-04-20 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US6103243A (en) * | 1985-05-15 | 2000-08-15 | Biotechnology Australia Pty, Ltd | Oral vaccines |
US6086880A (en) * | 1985-12-26 | 2000-07-11 | The University Of Saskatchewan | Rotavirus peptide compositions and methods of use |
CA1319101C (en) | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
US5554372A (en) * | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
ATE108067T1 (en) | 1986-09-22 | 1994-07-15 | Univ Emory | VACCINE AND METHOD OF MANUFACTURE. |
US5143726A (en) | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
GB8903313D0 (en) | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
EP0425082B1 (en) | 1989-09-04 | 1995-04-26 | Evans Medical Limited | Bordetella vaccines |
US5178882A (en) | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
US5334394A (en) | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
SE9003978D0 (en) | 1990-12-13 | 1990-12-13 | Henrik Garoff | DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION |
EP0563091A1 (en) | 1990-12-20 | 1993-10-06 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccines based on hepatitis b surface antigen |
GB9114003D0 (en) | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
ZA934199B (en) * | 1992-06-18 | 1994-01-10 | Akzo Nv | Carrier system against gnrh |
FR2695563B1 (en) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticles carrying antigens and their use for the induction of humoral or cellular responses. |
US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
US5928647A (en) | 1993-01-11 | 1999-07-27 | Dana-Farber Cancer Institute | Inducing cytotoxic T lymphocyte responses |
AU6172194A (en) | 1993-02-08 | 1994-08-29 | Paravax, Inc. | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
AT402898B (en) | 1994-08-08 | 1997-09-25 | Int Centre Genetic Eng & Bio | MOLECULAR PRESENTATION SYSTEM |
US5935821A (en) | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
EP0817854A2 (en) | 1995-03-31 | 1998-01-14 | Wolf, Hans, Prof. Dr. | Antigen presentation system based on retrovirus-like particles |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
JP3421970B2 (en) | 1996-03-01 | 2003-06-30 | ノバルティス アクチエンゲゼルシャフト | Peptide immunogen |
US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
AU753688B2 (en) * | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
AU745951B2 (en) | 1997-08-05 | 2002-04-11 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | New immunoprotective influenza antigen and its use in vaccination |
US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
US6231864B1 (en) | 1998-02-12 | 2001-05-15 | Immune Complex Corporation | Strategically modified hepatitis B core proteins and their derivatives |
JP2002509729A (en) | 1998-03-27 | 2002-04-02 | サイトス バイオテクノロジー アーゲー | Inducible alphavirus gene expression system |
US5990085A (en) | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
WO2000032227A2 (en) * | 1998-11-30 | 2000-06-08 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens, method of preparation and use |
TR200102493T2 (en) | 1999-02-25 | 2002-02-21 | Smithkline Beecham Biologicals S.A. | Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE. |
EP1532167B1 (en) | 2002-07-17 | 2012-01-25 | Cytos Biotechnology AG | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
JP5084103B2 (en) | 2002-07-18 | 2012-11-28 | サイトス バイオテクノロジー アーゲー | Hapten carrier conjugates and uses thereof |
PL375522A1 (en) | 2002-07-19 | 2005-11-28 | Cytos Biotechnology Ag | Ghrelin-carrier conjugates |
-
2001
- 2001-05-02 WO PCT/IB2001/000741 patent/WO2001085208A2/en active Application Filing
- 2001-05-02 AU AU2001252458A patent/AU2001252458A1/en not_active Abandoned
- 2001-05-02 EP EP01925778A patent/EP1278542A2/en not_active Withdrawn
- 2001-05-02 CA CA002407897A patent/CA2407897A1/en not_active Abandoned
- 2001-05-04 US US09/848,616 patent/US6964769B2/en not_active Expired - Fee Related
-
2005
- 2005-11-10 US US11/270,774 patent/US20060222652A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001085208A8 (en) | 2002-09-19 |
CA2407897A1 (en) | 2001-11-15 |
US20060222652A1 (en) | 2006-10-05 |
EP1278542A2 (en) | 2003-01-29 |
WO2001085208A2 (en) | 2001-11-15 |
US6964769B2 (en) | 2005-11-15 |
US20030054010A1 (en) | 2003-03-20 |
WO2001085208A3 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001252458A1 (en) | Molecular antigen arrays and vaccines | |
AU2002225681A1 (en) | Yeast-dentritic cell vaccines and uses thereof | |
AU3760100A (en) | Immunostimulatory nucleic acids and antigens | |
AU2001245504A1 (en) | Everting staple devices and methods | |
CY2009014I2 (en) | VACCINE AGAINST BACTERIAL ANTIGENS | |
IL151853A (en) | Multivalent antibodies and uses thereof | |
AU1951201A (en) | Peptide antigens | |
AU2002220473A1 (en) | Toughened plastics and its preparation method | |
AU2001290860A1 (en) | Spas-1 cancer antigen | |
AU2002211717A1 (en) | Stresscopins and their uses | |
AU2001271976A1 (en) | Microspheres and adjuvants for dna vaccine delivery | |
AU2002243392A1 (en) | Immunogenic proteoliposomes, and uses thereof | |
AU2001292936A1 (en) | Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines | |
AU2001248172A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
AU2002214150A1 (en) | Canine and feline tumour-associated antigen 5t4 | |
AU2001248176A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
AU2001248171A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
AU2002243314A1 (en) | Immunogenic cancer peptides and uses thereof | |
AU2001295185A1 (en) | Multiplexing-interleaving and demultiplexing-deinterleaving | |
AU7308200A (en) | Novel hev antigenic peptide and methods | |
AU2001259077A1 (en) | Immunomodulatory methods using carbohydrate antigens | |
AU2001295582A1 (en) | Tumour-related antigens | |
AU3283500A (en) | Tumor-associated antigen | |
AU2001272373A1 (en) | Cgtase and dna sequence encoding same | |
AU2001261317A1 (en) | Immunostimulant compositions and associated methods |